Rivaroxaban Data at the 2011 AHA Scientific Sessions
November 12 - 16, 2011
Orlando, Florida, USA
Results from the Phase III ATLAS ACS 2 TIMI 51 clinical trial of rivaroxaban (Xarelto®) have been presented in the Late Breaking Clinical Trials Session of the American Heart Association's Scientific Sessions 2011 by C. Michael Gibson, M.S., M.D., TIMI Study Group, Boston, MA, on Sunday, November 13, from 5:13 PM - 5:23 PM (ET).
On this occasion we held a conference call for investors and analysts on November 14, 2011 at approx. 12:30 p.m. CET (11:30 a.m. GMT).
Bayer's Xarelto® (Rivaroxaban) Meets Primary Efficacy Endpoint and Shows Significant Reduction in Mortality in Major ACS StudyRivaroxaban Meets Primary Efficacy Endpoint, Significantly Reducing the Composite of Cardiovascular Death, Myocardial Infarction and Stroke / Rivaroxaban 2.5 mg twice daily Significantly Reduced Both the Rate of Cardiovascular Death and the Incidence of All-Cause Mortality by more than 30% / Major Bleeding in Patients Receiving Rivaroxaban was Significantly Increased but there was no Increase in the Risk of Fatal Bleeding / Study Results Presented as a Late-Breaker at the Scientific Sessions of the American Heart Association and Published by the New England Journal of Medicine more
Monday, November 14:
Investor Conference Call on Rivaroxaban
Dr. Kemal Malik, Head of Global Development at Bayer HealthCare Pharmaceuticals
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations